ICT6401

ICT6401 is an autologous CAR-T cell therapy being developed by Innovative Cellular Therapeutics (ICT) for the treatment of autoimmune diseases. The therapy is built upon the company's proprietary CoupledCAR and InvivoCAR platforms, which are designed to enhance the expansion, persistence, and safety profile of engineered T cells. While the specific molecular target of ICT6401 remains undisclosed, the program aims to leverage the potency of CAR-T technology to deplete pathogenic cell populations responsible for autoimmune responses. As of early 2024, the candidate is in the pre-clinical stage, with an Investigational New Drug (IND) submission anticipated in the first half of 2027.